We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cigna, one of the largest employer-sponsored health benefits providers, saved its members $12 million on prescription drug costs in 2003 through generic drug conversion programs, the firm said.
Andrx has received conditional approval for its new mania and seizure treatment valproate delayed-release tablets, which is similar to brand firm Abbott Laboratories’ profitable drug Depakote.
Generic firm Synthon is free to launch a variation of GlaxoSmithKline’s (GSK’s) profitable antidepressant Paxil (paroxetine HCl) after the firms settled a patent dispute over the drug.
Generic firm Andrx announced it has received conditional approval from the FDA for its new mania and seizure treatment valproate delayed-release tablets, which is similar to brand firm Abbott Laboratories’ profitable drug Depakote.
Concerns about raw material used to make a generic version of Bristol-Myers Squibb’s diabetes drug Glucophage XR have prompted the FDA to withdraw the tentative approval it gave to Barr Pharmaceuticals, the firm said Jan. 9.
Not sitting idly by while one of its most successful painkillers prepares for generic launch, Purdue Pharma has petitioned the FDA to withhold final approval for a generic version of OxyContin until generic firms implement appropriate risk management plans (RMPs) and has filed its notice to appeal a recent court decision.
Provisions in the new Hatch-Waxman Act patent rules could provide a loophole for brand firms to delay generic competition by not listing all patents in the FDA’s Orange Book.
The FDA has granted generic firm Andrx conditional approval for its new mania and seizure treatment valproate delayed-release tablets, which is similar to brand firm Abbott Laboratories’ profitable drug Depakote.
With generic drugmakers expected to file a record number of applications this year, the FDA's Office of Generic Drugs (OGD) hopes not only to meet the increasing workload but to actually speed the approval process.
Barr Pharmaceuticals’ tentative approval for a generic version of Bristol-Myers Squibb’s diabetes drug Glucophage XR has been withdrawn by the FDA because of concerns over the pharmaceutical ingredients used to make the product, the firm said Jan. 9.